


1645



Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	09/932,538
Filing Date	August 17, 2001
First Named Inventor	Bell
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	37070/205236

Total Number of Pages in This Submission

RECEIVED
APR 16 2002
FBI CENTER 1600 2900

ENCLOSURES (check all that apply)

- | | | |
|--|---|---|
| <input type="checkbox"/> Fee Transmittal Form
<input type="checkbox"/> Fee Attached
<input type="checkbox"/> Amendment / Response
<input type="checkbox"/> After Final
<input type="checkbox"/> Affidavits/declaration(s)
<input type="checkbox"/> Extension of Time Request
<input type="checkbox"/> Express Abandonment Request
<input checked="" type="checkbox"/> Information Disclosure Statement
<input type="checkbox"/> Certified Copy of Priority Document(s)
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Assignment Papers (for an Application)
<input type="checkbox"/> Drawing(s)
<input type="checkbox"/> Licensing-related Papers
<input type="checkbox"/> Petition
<input type="checkbox"/> Petition to Convert to a Provisional Application
<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address
<input type="checkbox"/> Terminal Disclaimer
<input type="checkbox"/> Request for Refund
<input type="checkbox"/> CD, Number of CD(s) _____ | <input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
-Form PTO 1449 (six sheets)
-134 Publications
-Return Receipt Postcard |
|--|---|---|

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name
Kristin D. Mallatt, Reg. N. 46,895

Signature

Kristin Mallatt

Date

April 8, 2002

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: April 8, 2002

Typed or printed name
Emily Guida

Signature

Emily Guida

April 20, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



IDS/#5
4.25.02
RECEIVED
APR 16 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Steve Bell, et al.

Group Art Unit: 1645

Serial No.: 09/932538

Examiner:

Filed: August 17, 2001

For: CALCIUM PHOPSHATE PARTICLES
AS MUCOSAL ADJUVANTS

Attorney Docket No. 37070/205236

Date: 4/8/02

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants identify the documents listed on the modified Form PTO 1449 accompanying this submission. Copies of the cited documents are enclosed.

Remarks

Applicants do not concede that the identified materials constitute prior art within the meaning of the United States patent laws.

Applicants file this paper pursuant to 37 C.F.R. 1.97(b)(3), before issuance of a first Office action on the merits and, therefore, believe that no fee is due in connection with this filing. However, the Commissioner is authorized to debit Deposit Account No. 11-0855 for any such fee due should Applicants be mistaken.

Respectfully submitted,

Kristin D. Mallatt

Kristin D. Mallatt
Reg. No. 46.895

KILPATRICK STOCKTON LLP
Suite 2800, 1100 Peachtree Street
Atlanta, Georgia 30309-4530
(404) 815.6147



Sheet 1 of 1

TECH CENTER 1600/2900

APR 16 2002

RECEIVED


Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket No.: 37070/205236		Application No. 09/932,538			
		Applicant: Bell et al.					
		Filing Date: August 17, 2001		Group Art Unit 1645			
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Translation
		3,925,545	12/09/75	Relyveld			
		4,016,252	04/05/97	Relyveld			
		4,350,686	09/21/82	Relyveld, et al.			
		4,500,512	02/19/85	Barme			
		4,552,756	11/12/85	Relyveld, et al.			
		4,963,526	10/16/90	Ecanow			
		5,110,606	05/05/92	Geyer, et. al			
		5,178,882	01/12/93	Kossovsky et al.			
		5,219,577	06/15/93	Kossovsky et al.			
		5,306,508	04/26/94	Kossovsky et al.			
		5,334,394	08/02/94	Kossovsky et al.			
		5,364,838	11/15/94	Rubsamen			
		5,428,066	06/27/95	Larner, et al.			
		5,460,830	10/24/95	Kossovsky et al.			
		5,460,831	10/24/95	Kossovsky et al.			
		5,462,750	10/31/95	Kossovsky et al.			
		5,462,751	10/31/95	Kossovsky et al.			
		5,464,634	11/07/95	Kossovsky et al.			
		5,506,203	04/09/96	Backstrom et al.			
		5,549,973	08/27/96	Majetich et al.			
		5,580,859	12/03/96	Felgner et al.			
		5,593,875	01/14/97	Wurm, et al.			
		5,595,762	1/21/97	Derrieu et al.			
		5,618,800	04/08/97	Kabra, et al.			
		5,620,896	04/15/97	Herrmann et al.			
		5,629,021	05/13/97	Wright			
		5,641,515	06/24/97	Ramtoola			
		5,648,097	7/15/97	Nuwayser			
		5,665,382	09/09/97	Grinstaff, et al.			
		5,695,617	12/09/97	Gravier et al.			
		5,747,001	05/05/98	Wiedmann et al.			
		5,785,975	07/28/98	Parikh			
		5,824,638	10/20/98	Burnside, et al.			
		5,827,822	10/27/98	Floc'h et al.			
		5,843,887	12/01/98	Petit, et al.			
		5,858,398	01/12/99	Cho			
		5,866,553	02/02/99	Donnelly et al.			
		5,891,420	04/06/99	Cutie			
		5,898,028	04/27/99	Jensen et al.			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

RECEIVED


APR 16 2002

TECH CENTER 1600/2900


Sheet 2 of 6




Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket No.: 37070/205236		Application No. 09/932,538	
		Applicant: Bell et al.			
		Filing Date: August 17, 2001		Group Art Unit 1645	
		5,902,789	05/11/99	Stolz	
		5,985,312	11/16/99	Jacob, et al.	
		6,017,545	01/25/00	Modi	
		6,156,348	2/05/00	Santos, et al.	
		6,183,803	02/06/01	Morcoletal	
		6,187,335	02/13/01	Brey, et al.	
		6,355,271	03/12/02	Bell, et al.	
NON-U.S. PATENT DOCUMENTS					
Examiner Initial		Document Number	Date	Country	Class
		WO 90/11092	10/04/90		
		WO 93/17706	09/16/93		
		WO 93/24640	12/09/93		
		WO98/35562	08/20/98		
		WO00/15194	03/23/00		
		1422973		UK	
		7212036*	12/07/73	France	
		7924948**	04/17/81	France	
		WO 00/46147	08/10/00	PCT	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
		Abstracts of Papers Presented at the 1992 meeting on Modern Approaches to New Vaccines, Including Prevention of AIDS, Cold Spring Harbor, <i>Vaccine</i> 11: 92 (1993).			
		Abu-Izza, K.A., "Effect of gastrointestinal protein adsorption on the in vitro release of AZT from ethylcellulose microspheres," <i>Pharm. Dev. Technol.</i> , 3(4):49-501 (1998). (abstract)			
		Al-Achi, et al., "Erythrocytes as Oral Delivery Systems for Human Insulin," <i>Drug Development and Industrial Pharmacy</i> , 24(1):67-72 (1998)			
		Aldovini and R. A. Young, "Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines," <i>Nature</i> 351: 479-482 (1991).			
		Ascadi et al., "Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs," <i>Nature</i> 352: 815-818 (1991).			
		Bartus et al., "Sustained Delivery of Proteins for Novel Therapeutic Products," <i>Science</i> , 281(5380): 1161-1162 (1998).			
		Bastin, et al., "Use of Synthetic Peptides of Influenza Nucleoprotein to Define Epitopes Recognized by Class I-Restricted Cytotoxic T Lymphocytes," <i>J. Exp. Med.</i> , 165(4): 1508-1523 (1987).			
		Bayomi, M.A., "Preparation of casein-chitosan microspheres containing diltiazem hydrochloride by an aqueous coacervation technique," <i>Pharma. Acta. Helv.</i> , 73(4):187-92 (1998). (abstract)			
Examiner:			Date Considered:		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.					



Form PTO-1449		Docket No.: 37070/205236	Application No. 09/932,538
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Applicant: Bell et al.	
		Filing Date: August 17, 2001	Group Art Unit 1645
		Benvenisty, N., and Reshef, L. "Direct introduction of genes into rats and expression of genes," <i>PNAS</i> 83, 9551-9555, (1986)	
		Bennink and J. W. Yewdell, "Recombinant Vaccinia Viruses as Vectors for Studying T Lymphocyte Specificity and Function," <i>Curr. Top. Microbiol. Immunol.</i> , 163: 153-184 (1990)	
		Bulgarelli, et al., "Effect of matrix composition and process conditions on casein-gelatin beads floating properties," <i>Int. J. Pharm.</i> , 198(2):157-65 (2000). (abstract)	
		Bulgarelli, et al., "Casein/gelatin beads: I. Cross-linker solution composition effect on cross-linking degree," <i>Int. J. Pharm.</i> , 190(2):175-182 (1999). (abstract)	
		Carbone and Bevan, "Induction of Ovalbumin-specific cytotoxic T cells by in vivo peptide immunization," <i>J. Exp. Med.</i> , 169(1): 603-612 (1989).	
		Chen, et al., Comparison of albumin and casein microspheres as a carrier for doxorubicin, <i>J. PHARM. PHARMACOL.</i> , 39(12):978-85 (1987)	
		Choudhari, et al., Liposomes As a Carrier for Oral Administration of Insulin: Effect of Formulation Factors, 11 (3) <i>JOURNAL OF MICROENCAPSULATION</i> , 319-325 (1994)	
		Collins et al., "Processing of exogenous liposome-encapsulated antigens in vivo generates class I MCH-restricted T cell responses," <i>J. Immunol.</i> , 148(11): 3336-3341 (1992).	
		Cooney et al., "Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein," <i>Lancet</i> , 337: 567-572 (1991).	
		Cox et al., "Bovine Herpesvirus 1: Immune Responses in Mice and Cattle Injected with Plasmid DNA," 1993, <i>J. Virol.</i> , 67(9): 5664-5667.	
		Damge, et al., "New approach for Oral Administration Insulin With Polyalkylcyanoacrylate Nanocapsules as Drug Carrier," <i>Diabetes</i> , 37:246-251 (1988)	
		Damge, et al., "Poly(alkyl cyanoacrylate) Nanospheres for Oral Administration of Insulin," <i>J. Pharm. Sci.</i> , 86(12):1403-1409 (1997)	
		Deres, et al., "In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipoprotein vaccine," <i>Nature</i> , 342: 561-564 (1989).	
		Donnelly et al., "DNA Vaccines," <i>Annu. Rev. Immunol.</i> , 15: 617-648 (1997).	
		Edgington, "Turning On Tumor-Fighting T-Cells," <i>Biotechnology</i> , 11:1117-1119 (1993).	
		Edwards et al., "Large Porous Particles for Pulmonary Drug Delivery," <i>Science</i> , 276:1868-1871 (1997).	
		Friedman, T., "Progress toward human gene therapy," <i>Science</i> , 244, 1275-1281 (1989).	
		Furth et al., "Gene Transfer into Somatic Tissues by Jet Injection," <i>Analytical Biochemistry</i> , 205(2): 365-368, (1992).	
		Gardner et al., "Cell-mediated cytotoxicity against ectromelia virus-infected target cells," <i>Eur. J. Immunol.</i> , 4: 68-72 (1974).	
		Goto et al., "Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminum hydroxide with different physical properties," <i>Vaccine</i> , 15(12/13):1364-1371 (1997).	
		Hahn et al., "Infectious Sindbis virus transient expression vectors for studying antigen processing and presentation," <i>Proc. Natl. Acad. Sci. (USA)</i> 89: 2679-2683 (1992).	
		Hansen et al., "Strong Expression of Foreign Genes Following Direct Injection into Fish Muscle," <i>FEBS Lett.</i> 290, 73-76 (1991).	
Examiner:		Date Considered:	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.			



Form PTO-1449		Docket No.: 37070/205236	Application No. 09/932,538
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Applicant: Bell et al.	
		Filing Date: August 17, 2001	Group Art Unit 1645
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
		Heelan, et al., "In vitro analysis of the release of incorporated agents from sodium caseinate microspheres," <i>J. Microencapsul.</i> , 14(1):63-78 (1997). (abstract)	
		Hosny, et al., "Promotion of oral insulin adsorption in diabetic rabbits using pH-dependent coated capsules containing sodium cholate," <i>Pharm. Acta. Helv.</i> , 72(4):203-7 (1997). (abstract)	
		Hosny, "Hypoglycemic Effect Of Oral Insulin in Diabetic Rabbits Using pH-Dependent Coated Capsules Containing Sodium Salicylate Without And With Sodium Cholate," 24(3) <i>DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY</i> 24(3):307-311 (1998)	
		Kato et al., "Relationship between Hemolytic Activity and Adsorption Capacity of Aluminum Hydroxide and Calcium Phosphate as Immunological Adjuvants for Biologicals," <i>Microbiol. Immunol.</i> , 38(7): 543-548 (1994).	
		Kimura, et al., Oral Administration of Insulin as Poly(Vinyl Alcohol)-Gel Spheres in Diabetic Rats, 19(6) <i>BIOL. PHARM. BULLETIN</i> , 19(6):897-900 (1996). (abstract)	
		Kitsis et al., "Hormonal modulation of a gene injected into rat heart <i>in vivo</i> ," <i>Proc. Natl. Acad. Sci. (USA)</i> 88: 4138-4142 (1991).	
		Knepp, "Synthesis, properties, and intratumoral evaluation of mitoxantrone-loaded casein microspheres in Lewis lung cacimnoma," 45(10) <i>J. PHARM. PHARMACOL.</i> , 887-91 (1993). (abstract)	
		Latha, "Progesterone release from glutaraldehyde cross-linked casein microspheres: in vitro studies and in vivo response in rabbits," 61(5) <i>CONTRACEPTION</i> , 329-34 (2000). (abstract)	
		Latha, "Glutaraldehyde cross-linked bovine casein microspheres as a matrix for the controlled release of theophylline: in0vitro studie," 46(1) <i>J. PHARM. PHARMACOL.</i> , 8-13 (1994). (abstract)	
		Latha, et al., "Casein as a carrier matrix for 5- fluorouracil: drug release from microspheres, drug-protein conjugates and in-vivo degradation microspheres in rat muscle," 46(11) <i>J. PHARM. PHARMACOL.</i> , 858-62 (1994)	
		Latha, et al., "A new method for the synthesis of smooth, round, hydrophilic protein microspheres using low concentrations of polymeric dispersing agents," <i>J. Microencapsl.</i> , 12(1):7-12 (1995). (abstract)	
		Lin et al., "Expression of Recombinant Genes in Myocardium In Vivo after Direct Injection of DNA," <i>Circulation</i> 82(6): 2217-2221 (1990).	
		Lin and Askonas, "Biological properties of an influenza A virus-specific killer T cell clone," <i>J. Exp. Med.</i> 154(1): 225-234 (1981).	
		Lowman, "Oral Delivery of Insulin Using pH-Responsive Complexation Gels," 88(9) <i>JOURNAL OF PHARMACEUTICAL SCIENCES</i> , 933-937 (1999)	
		Maniatis, et al., " <i>Molecular Cloning</i> , A laboratory Manuel, 2 nd Edition," Cold Spring Harbor Laboratory Press, New York, 1.0 - 19.0 (1989). *	
		Mascola et al., "Surveillance of Listeriosis in Los Angeles County, 1985-1986," <i>Arch. Intern. Med.</i> , 149(7): 1569-1572 (1989).	
		McMichael et al., "Cytotoxic T-Cell Immunity to Influenza," <i>New Engl. J. Med.</i> , 309(1): 13-17 (1983).	
Examiner:		Date Considered:	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.			



Form PTO-1449		Docket No.: 37070/205236	Application No. 09/932,538
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Applicant: Bell et al.	
		Filing Date: August 17, 2001	Group Art Unit 1645
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
		McMichael et al., "Recognition of Influenza A virus Nucleoprotein by human cytotoxic T lymphocytes," <i>J. Gen. Virol.</i> , 67: 719-726 (1986).	
		Michel, et al., "The Effect of Site of Administration in the Gastrointestinal Tract on the Absorption of Insulin from Nanocapsules in Diabetic Rats," <i>J. Pharm. Pharmacol.</i> , 43:1-5 (1991)	
		Miller, "Retroviral Vectors," <i>Curr. Top. Microbiol. Immunol.</i> , 158, 3-24 (1992).	
		Musabayane, et al., Orally administered, insulin-loaded amidated pectin hydrogel beads sustain plasma concentrations of insulin in streptozotocin-diabetic rats, 164(1) <i>JOURNAL OF ENDOCRINOLOGY</i> , 1-6 (2000)	
		Naylor, et al., "Comparison of the mechanism of dissolution of hydrocortisone in simple and mixed micelle systems," <i>Pharm. Res.</i> 10(6):865-70 (1993). (abstract)	
		Olivares, et al., Effects of a Protective Hydrolyzed Casein Diet Upon the Metabolic and Secretory Responses of Pancreatic Islets to IL-1 β , Cytokine Production by Mesenteric Lymph Node Cells, Mitogenic and Biosynthetic Activities and Peyer's Patch Cells, and Mitogenic Activity and Pancreatic Lymph Node Cells from Control and Diabetes-Prone BB Rats, 68(3) <i>MOLECULAR GENETICS AND METABOLISM</i> 379-390 (1999)	
		Redfield et al., "Disseminated Vaccinia in a Military Recruit with Human Immunodeficiency Virus (HIV) Disease," <i>New Engl. J. Med.</i> , 316(11): 673-676 (1987).	
		Robinson et al., "Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA," <i>Vaccine</i> 11(9): 957-960 (1993).	
		Rowland, et al., "The stability of liposome's in vitro to pH, bile salts and pancreatic lipase," <i>Biochem. Biophys. Acta.</i> , 620(3):400-9 (1980)	
		Santinho, et al., Influence of formulation on the physiochemical properties of casein microparticles, 186(2) <i>INTL. JOURNAL OF PHARMACEUTICS</i> , 191-98 (1999)	
		Sato et al., "Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene Immunization," <i>Science</i> 273: 352-354 (1996).	
		Schafer et al., "Induction of a cellular immune response to a foreign antigen by a recombinant <i>Listeria monocytogenes</i> vaccine," <i>J. Immunol.</i> , 149(1):53-59 (1992).	
		Stover et al., "New use of BCG for recombinant vaccines," <i>Nature</i> 351: 456-460 (1991).	
		Takahashi et al., "Induction of CD8 cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs," <i>Nature</i> , 344: 873-875 (1990).	
		Tang et al., "Genetic immunization is a simple method for eliciting an immune response," <i>Nature</i> , 356: 152-154 (1992).	
		Taylor and Askonas, "Influenza nucleoprotein-specific cytotoxic T-cell clones are protective <i>in vivo</i> ," <i>Immunol.</i> , 58(1): 417-420 (1986).	
Examiner:		Date Considered:	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.			



Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket No.:	37070/205236	Application No.	09/932,538	
		Applicant:				Bell et al.
		Filing Date:	August 17, 2001	Group Art Unit	1645	
		Townsend, "Antigen recognition by class I-restricted T lymphocytes," <i>Annu. Rev. Immunol.</i> , 7: 601-624 (1989).				
		Townsend et al., "The Epitopes of Influenza Nucleoprotein Recognized by Cytotoxic T Lymphocytes Can Be Defined with Short Synthetic Peptides," <i>Cell</i> 44: 959-968 (1986).				
		Tozak, et al., "Chitosan Capsules for Colon-Specific Drug Delivery: Improvement of Insulin Absorption from the Rat Colon," <i>J. Pharm. Sci.</i> , 86(9):1016-1021 (1997)				
		Tragl, et al., "Oral administration of insulin by means of liposome's in animal experiments" (author's trans), <i>Wine Klin Wochenschr</i> , 91(13):448-51 (1979)				
		Ulmer, J. B. et al., "Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein," <i>Science</i> , 259: 1745-1749 (1993).				
		Wang et al., "Gene inoculation generates immune responses against human immunodeficiency virus type I," <i>P.N.A.S. USA</i> 90: 4156-4160 (May, 1993).				
		Wang, et al., "Enhanced type I immune response to a hepatitis B DNA vaccine by formulation with calcium- or aluminum phosphate," <i>Vaccine</i> , 18: 1227-1235 (2000).				
		Weiner et al., "Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization," <i>PNAS (USA)</i> 94(19): 10833-10837 (1997).				
		Willmott, et al., "Biodegradation rate of embolized protein microspheres in lung, liver and kidney of rats," <i>J. Pharm. Pharmacol.</i> , 41(7):433-438 (1989). (abstract)				
		Willmott, et al., Doxorubicin-loaded casein microspheres: protein nature of drug incorporation, 44(6) <i>J. PHARM. PHARACOL</i> , 472-75 (1992)				
		Wolff et al., "Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle," <i>Human Mol. Genet.</i> 1(6): 363-369 (1992).				
		Wolff et al., "Direct Gene Transfer into Mouse Muscle in Vivo," <i>Science</i> 247: 1465-1468 (1990).				
		Yap and Ada, "Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus," <i>Nature</i> , 273: 238-239 (1978).				
		Yewdell et al., "Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes," <i>Proc. Natl. Acad. Sci. (USA)</i> 82: 1785-1789 (1985).				
		Zhu et al., "Systemic Gene Expression After Intravenous DNA Delivery into Adult Mice," <i>Science</i> 261: 209-211 (1993).				
		http://vaxa.com/html/669.cfm				
Examiner:		Date Considered:				
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.						